Related Experiment Video
Updated: Aug 14, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma
1Department of Internal Medicine, New York Medical College, Metropolitan Hospital Center, New York, USA. fijabr@netzero.com
Abstract:
Acute tumor lysis syndrome (ATLS) is a well-known complication of chemotherapy in patients with rapidly proliferative hematopoietic malignancies such as lymphoma and leukemia. Rituximab anti-CD20 monoclonal antibody, an alternative to chemotherapy in the treatment of low-grade follicular lymphoma, also has been associated with ATLS. Rituximab-induced ATLS has been reported in 2 patients with chronic lymphocytic leukemia and in 2 patients with non-Hodgkin's lymphoma. I report another case of rituximab-induced ATLS in a patient with diffuse large B-cell lymphoma and review the cases in the literature.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...